Table 3.

Pharmacokinetic drug interactions with edoxaban [27–29]

Concomitant drug	Effects on pharmacokinetics	Dose considerations
Verapamil	Increase in AUC0–24: 52.7% Increase in C max: 53.3% Increase in 24-h concentration: 29.1%	VTE: dose should be halved NVAF: dose should be halved
Quinidine	Increase in AUC0–24: 76.7% Increase in C max: 85.4% Increase in 24-h concentration: 11.8%	VTE: dose should be halved NVAF: dose should be halved
Dronedarone	Increase in AUC0–inf: 84.5% Increase in C max: 45.8% Increase in 24-h concentration: 157.6%	VTE: use is not recommended NVAF: dose should be halved
Amiodarone	Increase in AUC0–inf: 39.8% Increase in C max: 66.0% Decrease in 24-h concentration: 25.7%	No dose adjustment
Digoxin	Increase in AUC0–τ: 9.5% Increase in C max: 15.6% Decrease in 24-h concentration: 9.4%	No dose adjustment
Atorvastatin	Increase in AUC0–inf: 1.7% Decrease in C max: 14.2% Increase in 24-h concentration: 7.9%	No dose adjustment
Ketoconazole	Increase in AUC0-inf: 86.7% Increase in C max: 66.9% Increase in 24-h concentration: 26.8%	VTE: dose should be halved NVAF: concomitant use should be avoided
Erythromycin	Increase in AUC0–inf: 87.0% Increase in C max: 63.1% Increase in 24-h concentration: 27.8%	VTE: dose should be halved NVAF: concomitant use should be avoided

AUC area under the curve, C _max maximum concentration, NVAF non-valvular atrial fibrillation, h hour